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Abstract
Based on a careful literature search a review is presented of the history, background, concepts and current
use of comedication and polypharmacy in psychiatry. The pros and cons of comedication and polyphar-
macy are presented, as well as their apparent increase in recent times. Possible reasons for the increase
of comedication/polypharmacy are described. Both the potential advantages as well as the potential
risks are discussed. The one sided view that all comedication/polypharmacy is nothing but problematic
is questioned. Comedication/polypharmacy seems to be, among others, the current answer to the well-
known limited efficacy and effectiveness of current monotherapy treatment strategies.
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Introduction
With the invention of antipsychotic, antidepressive,
tranquilizing and mood stabilizing medications in the
1950s, psychopharmacological treatment became
one of the main treatment approaches in psychiatry,
if not the most important. This was, in principle, a suc-
cess story, but several limitations, such as delayed
onset of efficacy, unsatisfactory efficacy, tolerability
problems, and so on. were also observed. In the last 20
to 30 years second generation antipsychotics (SGAs)
and antidepressants have entered the market, devel-
oped to overcome some of these problems. However,
the progress made is primarily related to better toler-
ability rather than efficacy. There are still several
unmet needs which can hopefully be reduced signifi-
cantly in psychopharmacological treatments in the
near future (Tandon et al., 2008; Möller, 2010, 2011,
2012).
Along with the development of new/better and
more specific compounds, comedication/polypharmacy
has been, and is still, a widely used strategy to
overcome the limitations of monotherapy with the cur-
rently available psychotropic drugs. This paper aims
to describe the background and history as well as the
concepts and the current status of comedication/
polypharmacy, focusing on the field of schizophrenia
and depression. Generally speaking, comedication/
polypharmacy is a very common phenomenon for dif-
ferent reasons, and is difficult to reduce (Stahl, 1999a,
b; Viola et al., 2004; Biancosino et al., 2005; Barbui
et al., 2006; Russell et al., 2006; Megna et al., 2007;
Pandurangi and Dalkilic, 2008; Thompson et al.,
2008; Alda and Yatham, 2009; Glezer et al., 2009;
Goldberg et al., 2009; McIntyre and Jerrell, 2009;
Mistler et al., 2009; Shelton et al., 2010).
Limitations of drug treatment in schizophrenia
and depression as one possible background
for comedication/polypharmacy
In general, medicine polypharmacy, e.g. in the treat-
ment of hypertension, of diabetes or in the antibiotic
treatment of infections, has nowadays become more a
rule than an exception. Antibiotic combination regi-
mens, for example, with different specific modes of
action, are often chosen to cover a spectrum of different
pathogens at once, or to manage drug resistant bac-
teria. The ideal equivalent approach in psychiatry
would be to target specific symptom clusters or
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comorbidities by combining psychopharmacologic
drugs specifically targeting the underlying key neuro-
transmitters. Unfortunately, the situation in psychiatry
is more complex, as syndromes and symptoms cannot
easily be reduced to single neurotransmitters. On the
other side, the development of biological psychiatric
illness concepts, with the consideration of specific
neurotransmitters, went hand in hand with the devel-
opment of the first psychotropic drugs.
Since the development of chlorpromazine, anti-
psychotics have formed the basis of schizophrenia
treatment for more than 50 years (Möller, 2010). In
terms of their chemical structure, antipsychotics, tra-
ditionally called neuroleptics, are a heterogeneous
group of psychoactive drugs and include pheno-
thiazines, thioxanthenes, butyrophenones, diphenyl-
butylpiperidines, benzamides, benzisoxazoles and
dibenzepines (Möller, 2012). They are used in acute
phase treatment as well as for long-term treatment
and prevention of relapses (Falkai et al., 2005, 2006).
Based on the clinical efficacy of neuroleptics, the
dopamine hypothesis was developed. It implies that
in patients with schizophrenia there is an increased
production of this neurotransmitter (Schmitt et al.,
2008) or an over-sensitivity of dopamine receptors in
certain brain regions (especially the mesolimbic sys-
tem) resulting in the appearance of positive symptoms,
along with a hypodopaminergic state in frontal brain
regions associated with negative symptoms (Sedvall
and Farde, 1995). The hypothesis of a hyperdopami-
nergic state is supported by the successful treatment
of psychotic symptoms by neuroleptics which are
antagonists of D2 receptors. Besides dopamine, other
neurotransmitters, like serotonin (5-HT) and gluta-
mate, seem to be involved in the pathophysiology
of schizophrenia (Möller, 2008c). The blockade of
5-HT2A receptors and the preferential blockade of
specific subtypes of dopamine receptors was hypoth-
esized to be a relevant mechanism for treating negative
symptoms (Möller, 2003), especially in the develop-
ment of SGAs in the last two decades.
Although SGAs represent an important progress in
the medication of schizophrenia, especially concerning
lower EPS liabilities, and to a lesser degree concerning
superior efficacy and a broader spectrum of efficacy,
the latter results have in no way fulfilled the expec-
tations which were primarily associated with the
advent of the SGAs (Tandon et al., 2008). Another pro-
blem is that at least some of the SGAs induce weight
gain to a remarkable degree, and this is associated
with metabolic risks (De Hert et al., 2009). Clozapine
still seems to be the best representative of the SGAs
in various aspects, especially regarding the efficacy in
refractory patients, but it is also associated with high
risk of weight gain and lower risk of agranulocytosis,
with a possibly fatal outcome. Thus, there is still
an urgent need to solve the unmet needs of current
drug treatments for schizophrenia. This includes the
following: better efficacy for negative symptoms, better
efficacy for cognitive disturbances, better efficacy
for depressive symptoms, better efficacy in refractory
patients, no weight gain or associated metabolic issues,
excellent general tolerability and safety, an improved
acceptance by patients and an increased subjective
well-being/quality of life.
The development of the SGAs and their claim for a
broader clinical efficacy (Agid et al., 2008) was based
on the concept that the multiple symptom domains
of schizophrenia could be effectively treated with a
single agent, demonstrating heterogeneous pharmaco-
logical intervention in the sense of ‘intra molecular
polypharmacy’ (Kim et al., 2009). However, more
and more evidence arises that, at least at present, this
concept is difficult to realize with the currently avail-
able compounds. Instead, there is increasing support
for the notion of possibly using multiple compounds,
each for a specific syndrome. In the line of this thinking
it is interesting that the American drug authority, the
FDA, has, for the first time, endorsed the possibility
of approving drugs that might be used in conjunction
with antipsychotics, if a clear efficacy in the treatment
of special syndrome domains, such as negative or cog-
nitive symptoms, can be demonstrated (Laughren and
Levin, 2006). It is still assumed to be possible that
different symptom domains within schizophrenia can
be mediated through a common pathophysiological
mechanism, supporting the position that a non-
selective intervention with compounds targeting
multiple receptors can translate to broad clinical
improvement. Alternatively, and in line with the men-
tioned shift in drug development, schizophrenia may
well represent a collection of different pathophysiolo-
gical mechanisms, and optimal treatment in the future
will probably include different agents, each uniquely
targeting a specific dimension of schizophrenia, with
treatment tailored for the individual patient (Kapur
and Mamo, 2003). Current drug developments for anti-
psychotics are going in the direction of multi-receptor
compounds involving the dopaminergic and sero-
tonergic system in searching for new frontiers, with
special focus on the glutamatergic system (Arranz
and Kerwin, 2003; Miyamoto et al., 2005; Arranz and
de Leon, 2007; Möller, 2010). Positive study results in
treatment-resistant schizophrenia patients for cloza-
pine augmentation with glutamatergic substances
such as lamotrigine and CX516 seem to give support
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to this hypothesis (Sommer et al., 2012). These reflec-
tions on the present situation and the future of medi-
cation to treat schizophrenia are necessary to
understand the basis for some demands in this field,
and possible ways to answer these with an ‘intra mol-
ecular polypharmacy’ or by combining two or more
compounds (Kim et al., 2009). The field of schizo-
phrenic medication is chosen here as an example.
These principal thoughts can easily be extended to
other areas as well.
In terms of depression medication, imipramine, the
first antidepressant, as well as several other traditional
tricyclic antidepressants, such as amytriptyline and
doxepin, have a broad spectrum of pharmacological
properties: apart from reuptake inhibition of serotonin
and noradrenalin they also have receptor blocking
properties, e.g. on the muscarinergic and histaminergic
receptors. These latter might be primarily side effect
related, but they might also contribute to the clinical
efficacy profile in the sense of ‘intramolecular polyphar-
macy’ mentioned above (Kim et al., 2009). Since the
development of imipramine more than 50 years ago,
antidepressants have been seen as standard treatment
for patients suffering from depression (Möller, 2010).
Related to current diagnostic categories of depression,
‘major depression’ (DSM IV) or ‘depressive episode’
(ICD 10) are the main indications for treatment
with antidepressants, especially those of moderate or
severe intensity (Möller et al., 2011). Depression is
explained by a complex aetiopathogenesis involving,
among other things, genetic dispositions and psychoso-
cial stressors as well as alterations of the serotonergic,
noradrenergic and dopaminergic transmitter systems.
Dysthymia and depressive adjustment disorders, pri-
marily related to psychosocial stress factors in early
life or in the current life situation, do not respond as
well to antidepressive compounds (Möller, 2009a;
Rush et al., 2009). The monoamine-oxidase (MAO)
inhibitors seem to have special indication in atypical
depression (Henkel et al., 2006).
The efficacy of the traditional antidepressants
(ADs) (mostly tricyclics) and modern antidepressants
(mostly SSRIs and SNRIs) is well proven. However,
the efficacy of modern ADs has been criticised as too
low regarding clinical relevance by some authors
(Kirsch et al., 2008), a criticism that can be rejected
when carefully reviewing all data (Möller, 2008b;
Fountoulakis and Möller, 2011). Nevertheless, the
pre-post-differences between antidepressant treatment
and placebo is only in the range of 2–3 points in the
Hamilton Depression Rating Scale (HAMD) and the
placebo-verum differences of response rates are only
in the range of 15–20%, depending on the type of
antidepressant, severity of depression, etc. (Möller,
2008a), suggesting that future compounds with greater
efficacy are needed. Compared to the pharmacological
mechanisms of the first and second generation of anti-
depressants, the recently licensed antidepressant ago-
melatine can be judged to be an innovative approach:
a melatonin MT1 and MT2 agonist and a 5-HT2c antag-
onist with a special focus on sleep and circadian
rhythm disorder which are a relevant subcomponent
of depressive symptoms (Eser et al., 2007; Kasper
et al., 2010; Kennedy and Rizvi, 2010).
Just as in the field of drug treatment of schizo-
phrenia, there are also still serious unmet needs in
the treatment of depression, despite the introduction
of the selective serotonin reuptake inhibitors (SSRIs)
and other modern antidepressants, including also the
recently introduced agomelatine, which has improved
some aspects of depression treatment, predominantly
in terms of side effects. The most relevant unmet
needs in the treatment of patients with depression
are delayed onset of response, limitations in the
effectiveness, limitations in achieving remission, an
unsatisfactory high proportion of poor responders/
non-responders and tolerability issues, depending on
the class of antidepressants. Thus, there are still good
reasons for further drug development in this field,
which lead in different directions. Some are based on
the traditional transmitter hypothesis; others are
focusing on new targets such as interventions on the
stress hormone axis, the neurokinin system or the
glutamatergic system (Schechter et al., 2005; Norman
and Burrows, 2007; Millan, 2009). It seems that so
far efforts have been made to overcome some of the
described clinical treatment problems by comedica-
tion/polypharmacy.
General aspects and concepts of comedication/
polypharmacy
The terms comedication and polypharmacy are not
well defined and are used in somewhat different
ways, hampering a consensus understanding of the
approaches. According to Preskorn and Lacey (2007)
clinicians use polypharmacy for several reasons:
1. To treat two pathophysiologically distinct but
comorbid illnesses in the same patient;
2. To treat the same condition or two ‘comorbid’ syn-
dromes (e.g. major depression plus panic disorder)
in the same patient;
3. To increase the efficacy of the primary treatment
by e.g. combining a selective serotonin reuptake
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e.g. mirtazapine to treat a patient with major
depression;
4. To provide acute amelioration while awaiting the
delayed effect of another medication, e.g. using
lorazepam in acute mania while waiting for the anti-
manic effects of a mood stabilizer;
5. To treat intervening acute phases of an illness,
e.g. adding an antidepressant to a mood stabilizer
when a bipolar patient develops a depressive
episode;
6. To treat adverse events produced by the primary
drug, e.g. adding an anticholinergic when a patient
develops dystonia on a neuroleptic;
7. To switch medication from one compound to
another with a limited overlapping time.
Comedication is often used in the sense of com-
bining two medications with the same indication, e.g.
two antidepressants or two antipsychotics. A special
type of comedication, the combined treatment of a
medication for a given indication (e.g. antidepressant)
with a compound with another indication (e.g. anti-
psychotic) to increase efficacy, is often called augmen-
tation. In most cases comedication strategies are
performed to increase efficacy in general, to improve
efficacy in a certain subdomain (e.g. negative symp-
toms in schizophrenia) or to reduce side-effects
(Table 1). From a clinical viewpoint this seems rational
under certain conditions, e.g. at least some proof of
efficacy for the comedication strategy and no unaccep-
table side effect burden (Preskorn and Lacey, 2007). In
this sense several guidelines describe some comedica-
tions as meaningful, especially to overcome treatment
resistance (Falkai et al., 2005, 2006; Bauer et al., 2007).
Especially in the acute and long-term treatment of
bipolar disorder (Grunze et al., 2002, 2004, 2010) not
only dual but, under certain conditions, even triple
combinations are described as indicated: e.g.
combination of an antidepressant and a mood stabil-
izer in the treatment of acute bipolar depression, and
the combination of, if necessary, up to three mood
stabilizers in the maintenance therapy of bipolar
disorder.
Generally, the questions arise as to where poly-
pharmacy starts; how many compounds need to be
applied to declare the respective treatment regime as
‘polypharmacy’. This has not been defined so far in
a consistent way. Some authors suggest that the combi-
nation of three or more medications for the same
indication should be called ‘polypharmacy’. While
comedications under the above described conditions
still have some rationality, polypharmacy already
seems to have a bad reputation in terms of irrationality,
harmfulness, etc., even though in a given case it might
be meaningful to combine different compounds to
achieve greater efficacy (Stahl, 1999a).
An even more frequent problem than the general
question of the usefulness and advantage of comedica-
tion and polypharmacy is their use and application in
patients who suffer from not one mental disorder, but
a combination of mental disorders or a combination of
mental disorders and somatic disorders, such as meta-
bolic disorders, vascular disorders, etc. If each of these
conditions is treated with one medication, this is, of
course, fully rational. Nevertheless it can lead to an
increased side effect burden, to compliance problems
due to complicated regimens of different medications
at different times and to problems of pharmacody-
namic and pharmacokinetic interactions, especially
related to enzyme induction and inhibition, which
should be carefully taken into account by the treating
doctor. This might become especially problematic in
elderly patients with much comorbidity. In these
patients multiple doctors often prescribe medications




Especially in the light of evidence-based medicine
(Gören et al., 2008; Möller and Maier, 2010), the key cri-
terion for rationality of comedication (Preskorn and
Lacey, 2007) is that results from adequate clinical trials
are able to prove superior efficacy (Tables 2 and 3).
Relevant clinical data on the advantage of comedica-
tion is available for only few combination regimes,
e.g. lithium augmentation, thyroxine augmentation
or augmentation with antipsychotics in the treatment
of refractory depression (Crossley and Bauer, 2007;
Nelson and Papakostas, 2009) and also for some
Table 1. What drives clinicians to comedication/
polypharmacy?
û Delayed onset of action
û Limited efficacy in terms of pre-post score changes
û Insufficient drug effect (in terms of response/remission)
û Insufficient drug response in terms of special syndromes
of a complex symptomatology, e.g. sleep disturbances or
anxiety in depression, depressive or negative symptoms in
schizophrenia
û Non-response, treatment resistance
û Irrational expectations of treatment outcome
û Comorbidities
û ‘Antidotes’ against side effects
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other conditions such as resistant schizophrenia
(Honer et al., 2006; Suzuki et al., 2008).
Sometimes the data that is available shows neither
an improvement nor a worsening of the clinical con-
dition (Glick et al., 2006; Adan-Manes and Garcia-
Parajua, 2009). This might be ‘real’ or due only to
insufficient statistical power in the respective trials
(Möller and Maier, 2010). For other conditions data
are more or less lacking and doctors rely more on
their own clinical experience than on the results of
clinical trials (Möller et al., 2004; Blier et al., 2010).
For example, and against all expectations, comedica-
tion with an antidepressant in patients with schizo-
phrenia additionally suffering from a depressive
syndrome is far from proven (Whitehead et al., 2002).
Examples are naturalistic studies reporting that
patients suffering from depressive symptoms were
intuitively treated with significantly more antidepress-
ant compounds which, nevertheless, did not keep
these patients from suffering a worse course of illness
due to greater illness severity.
Generally, it needs to be critically discussed whether
or not clinicians can base their decision in terms of
polypharmacy on theoretical assumptions of a possible
advantage or on some positive clinical experience, or if
the use of polypharmacy is only justified by evidence-
based medicine. For example, what about plausible
theoretical arguments, e.g. the combination of a weak
D2 receptor antagonist such as quetiapine with a
strong D2 receptor antagonist (like risperidone) in
refractory acute psychotic patients, which nonetheless
lacks empirical data? Is evidence-based medicine poss-
ibly going too far with its demands, destroying the
positive impact of theoretical considerations and
clinical experiences (Möller, 2009b; Möller and Maier,
2010)? Some of these suggestions seem meaningful,
whereas others seem to be too rigid, e.g. the demand
for only one mechanism of action for each medication.
An additional condition, not mentioned in the list
above, which is that the combination should be cost
effective, seems plausible but is probably difficult to
fulfil, since the relevant data might not be available.
Of interest are the guidelines for using a combi-
nation based on the n=1 trial in clinical practice,
described in the paper by Preskorn and Lacey (2007),
which come very close to everyday clinical practice:
(1) Each drug has individually been given an adequate
trial and has been found to be inadequately
effective
(2) The combination meets most of the criteria for
rational polypharmacy in psychiatry and, ideally,
has supporting data from the literature as to its
efficacy, safety and tolerability
(3) The combination is found to be superior overall to
either agent alone in terms of efficacy, safety and
tolerability
(4) After a period of stabilization, a trial is made to
taper one of the agents to test the continued need
for combination therapy
Irrationality probably has to be considered, if the
comedication leads to reduced plasma levels of the
first medication (de Leon, 2004), as is often the case
during the combination of an antipsychotic with carba-
mazepine. However, this combination might also
increase efficacy, e.g. in mania, and might then be
acceptable, despite the negative pharmacokinetic
interactions.
An interesting theoretical approach in this context
is the concept of intra molecular polypharmacy sug-
gested by Stahl (2008), realised in some of the ‘rich
drugs’ like the SGAs, which are intervening in different
neuropharmacological circuits, reducing not only
psychotic symptoms, but also depressive symptoms
(Möller, 2005). This could be seen as an indication
that a more selective pharmacological intervention
focussing only on the most relevant transmitter system
for schizophrenia, the dopaminergic system, might not
be sufficient to reduce some symptom domains of
schizophrenic psychosis. If this is accepted, why not
allow, instead of treatment with a rich compound, a
treatment with a selective compound plus a meaning-
ful comedication.
This line of thinking leads to other questions which
can probably not be answered at present. Was the intro-
duction of selective antidepressants, like the SSRIs,
associated with an increase of comedications? Was
the introduction of the antipsychotics with a rich
pharmacological profile, like most SGAs, associated
Table 2. Principle aspects for rationality/irrationality of
comedication/polypharmacy (CM/PP)
û Proven/unproven superior efficacy of CM/PP in terms of
EBM
û Proven/unproven superior efficacy of CM/PP in terms of
clinical experience
û Pharmacological plausibility/implausibility of CM/PP
► Positive example: Combination of a weak D2 blocker
with a strong D2 blocker
û Consideration/non-consideration of pharmacokinetic
and/or pharmacodynamic problems of CM/PP
► Negative example: The combination leads to reduced
plasma levels of the first-rank drug treatment
û Non-detection of non-compliance or too low plasma levels
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with a reduction in comedication? There is a strong
impression that there is an increase of comedication/
polypharmacy in both fields – both in the treatment
of depression and in the treatment of schizophrenia.
Given the hypothesis that modern highly specific
antidepressants are weaker and modern antipsychotics
(‘rich drugs’) are stronger in their goal of efficacy than
their traditional counterparts (Leucht et al., 2009;
Baghai et al., 2011; Möller et al., 2012), this does not
explain the general increase in comedication/polyphar-
macy. The increase of comedication/polypharmacy
might be, at least to a certain degree, driven by reasons
other than the pharmacological properties or the
efficacy of the respective compounds. The increased
expectations for remission and recovery might play
a role, as both outcome criteria are the goal in
both schizophrenia and depression. Additionally, the
majority of psychiatric patients are usually treated by
non-psychiatrists. Treating depression, for example,
has become relatively easy these days. Primary care
physicians can choose from a variety of very good
first-line options, with easy dosage regimens and
good tolerability profiles (usually SSRIs). Many
patients will experience an improvement, if not com-
plete remission, of their symptoms. As a consequence,
the more refractory and resistant cases are left to
the psychiatrists, and these are usually also the very
patients requiring comedication/polypharmacy.
Another possible explanation might be that, at pre-
sent, doctors stick more to the licensed dose of single
compounds, possibly reducing their potential efficacy,
whereas, in the past, very often much higher doses
were used, which might have resulted in greater
efficacy of the compounds. A reminder of this tradition
is the CATIE study (Lieberman et al., 2005), where
olanzapine was used up to 30mg/p.d. (licensed dose
20mg/p.d.); it showed the best results in this study
compared to the other antipsychotics, for which the
licensed dose was respected.
Prevalence of comedication/polypharmacy
Comedication and polypharmacy seem to have
been well recognized phenomena, and problems
seem to have existed in earlier times, when there was
no theoretically-based pharmacotherapy. This can be
seen from the following quotations: ‘Polypharmacy
is not unique to psychiatry, or to the present era of
drug treatment. Over a hundred years ago, William
Osler (1898, cited in Paris, 2010) criticized his col-
leagues for treating patients with ‘shotgun’ methods,
giving drugs to manage each symptom separately
and focussing on symptoms rather than on a disease
process. Osler’s comments still apply to the practice
of medicine.’ (Paris, 2010). A careful literature search
using the terms comedication, polypharmacy and
psychopharmacology gives only a little information
on the history of comedication/polypharmacy in psy-
chiatry. Therefore, we are far away from being able
to write a history of this phenomenon.
From my own experience as a doctor who has
worked in psychiatry since the beginning of the
1970s, I can say that already at that time it was com-
mon practice to use certain combinations. For example,
in a large state hospital close to Munich, severely
acute, mostly agitated or even aggressive psychotic
in-patients were treated initially with an injection com-
bining haloperidol, chlorpromazine and promethazine.
In-patients suffering from severe depression were
treated with a tricyclic antidepressant and a benzo-
diazepine to reduce anxiety and sleep disturbances
from the beginning.
The earliest systematic data in Germany are avail-
able from the years 1979–1989. They are based on the
Table 3. Criteria for rational co-pharmacy in psychiatry (Modified according to Preskorn and Lacey, 2007)
û Knowledge that the combination has a positive effect on the pathophysiology of the disorder
û Convincing evidence that the combination is more effective than monotherapy
û The combination should not pose significantly greater safety or tolerability risks than monotherapy
û Drugs should not interact both pharmacokinetically and pharmacodynamically
û Drugs should have mechanisms of action that are likely to interact in a way that augments response
û Drugs should have only one mechanism of action
û Drugs should not have a broad-acting mechanism of action
û Drugs should not have the same mechanism of action
û Drugs should not have opposing mechanisms of action
û Each drug should have simple metabolism
û Each drug should have an intermediate half-life
û Each drug should have linear pharmacokinetics
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German drug surveillance system, Arzneimittel
Überwachung Psychiatrie (AMÜP). Tables 4 and 5
show the most frequently used antipsychotics or anti-
depressants, respectively, as well as the doses, mean
duration of treatment and some preferred drug combi-
nations (Grohmann et al., 1994, 2004a,b).
Interestingly, in the group of haloperidol-treated
patients (Table 4) the most common comedication
treatment is biperiden (to reduce EPS), while clozapine
is, as expected, only rarely combined with biperiden.
There is a high tendency to combine one neuroleptic
with another one. One reason for this is that, as
pointed out above, haloperidol is often combined in
acute psychotic patients with a more sedative phe-
nothiazine like levomepromazine. Nearly all neuro-
leptic agents, apart from clozapine, are combined in
about 20% of patients with an antidepressant, probably
either for reasons of a depression or a negative
syndrome.
As to the data on antidepressants (Table 5), the high
prevalence of combinations with benzodiazepines –
depending on the respective antidepressants between
20 and 50% – is remarkable. It seems somewhat counter-
intuitive that the most sedative antidepressants such
as amitriptyline and doxepine have the highest co-
medication. Considering that these are naturalistic
data, this can probably be explained by the fact that
these were patients with severe depression associated
with anxiety and sleep disorders, for whom these
sedative antidepressants were selected along with the
benzodiazepine comedication. Results from random-
ized control trials (RCTs) and naturalistic studies
suggest that the combination of an antidepressant com-
poundwith benzodiazepines can lead to a faster onset of
action (Henkel et al., 2009), andmight subsequently also
be protective in terms of emergent suicidal thoughts
(Seemüller et al., 2010b). The high comedication rate
(around 50%)with neuroleptics is astonishing. This can-
not only be due to psychotic depression, which does not
have such aprevalence, butprobablyalso to the fact, that
in those days, inGermany, so called ‘lowpotency neuro-
leptics’ suchas thioridazinewereoftenprescribedas sur-
rogates for benzodiazepines to reduce agitation and
sleep disturbances.
Table 4. AMÜP drug surveillance study (1979–1989): Most frequently used neuroleptics (n>900) in all patients (mean daily doses
(MDD), mean duration of treatment (MDT) and combination data)
n
MDD MDT Plus other antipsychotic Plus biperiden Plus antidepressant
mg/d d >1 d (%) >1 d (%) >1 d (%)
Haloperidol 5229 15.4 26 74.8 50.9 22.3
Perazine 4778 302 32 59.4 23.2 26.3
Levomepromazine 3165 107 13 81.5 32.4 18.5
Thioridazine 1089 179 23 48.1 17.6 24.1
Fluspirilene 1019 – – 81.2 37.9 13.5
Clozapine 967 205 46 58.6 18.2 6.3
Table 5. AMÜP drug surveillance study (1979–1989): Most frequently used
antidepressants (n>800) in all patients (mean daily doses (MDD), mean duration of
treatment (MDT) and combination data
n
MDD MDT Plus BZD Plus AP
mg d >1 d (%) >1 d (%)
Amitriptyline 2658 109 33 49 52
Clomipramine 1319 111 36 26 47
Doxepine 893 98 22 48 46
Maprotiline 863 108 32 21 38
Tranylcypromine 803 17 32 37 90**
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Most recently, a double-blind randomized con-
trolled trial reported significantly faster onset of the
antidepressant action of citalopram when combined
with doses of the low potency neuroleptic pipamper-
one, providing fresh evidence for this former clinical
practice. The authors consider that at especially low
dosages pipamperone might act as a highly potent
5-HT2a/D4 receptor antagonist, which might lead to
an acceleration of the onset of action (Wade et al.,
2011). In particular, the positive effect of this com-
bination for symptoms such as sleep disturbance,
reduced appetite, concentration difficulties and pessi-
mistic thoughts seems to be responsible for this early
symptom improvement (Wade et al., 2011). However,
it needs to be underlined that the comedication is
also often time limited. For example, in the above
mentioned naturalistic study of depressed inpatients,
about 59% of all patients received a comedication
with a benzodiazepine and about 45% received a
comedication with an antipsychotic (Seemüller et al.,
2010a). However, on discharge, comedication rates
for tranquilizers (10.6%) as well as for neuroleptics
(13.2%) decreased markedly (Fig. 1).
Data from the successor of the AMÜP system, the
Arzneimittelsicherheit in der Psychiatrie (AMSP)
(Stübner et al., 2010) cover the more recent years of
pharmacopsychiatry in Germany, starting in 1994
and going up to 2009. The data, so far unpublished,
show that comedication is increasing. Most remark-
ably, polypharmacy in the sense of more than four
psychotropic medications has increased (Fig. 2).
Table 6 and Figures 3–5 show details of combinations
in depression and schizophrenia in a more detailed
way. All this reflects the treatment strategies involved
in the different university and non-university psychia-
tric hospitals, and means it can probably not be
explained by clinical practice alone, but might have
several reasons in the sense discussed above. There
are not many differences in the prevalence for comedi-
cation/polypharmacy between different settings such
as university hospitals, state hospitals or psychiatric
departments in general hospitals. In the AMSP
system psychiatric hospitals not only from Germany,
but also from Austria and Switzerland are involved.
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Fig. 1. Antidepressant treatment combinations at discharge from inpatient treatment (n=1014) (AD, antidepressant; AP,
antipsychotic compound).
Table 6. AMSP Schizophrenia 2009: main combination of
antipsychotics (Atyp AP=atypical antipsychotic, typ.-low
potency=typical low potency antipsychotic, typ.-high
potency=typical high potency antipsychotic)
% schizo % atyp AP
Atyp AP+typ.-low potency 32.8 39.2
Atyp AP+atyp Ap 27.8 33.3
Atyp AP+typ.-high potency 20.8 24.8
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Fig. 2. Prevalence of comedication/polypharmacy with psychotropic drugs (PTD) in inpatients treated with psychopharmaca














Fig. 3. Prevalence of combination of antidepressants with other psychopharmaca in % of depressed inpatients. Data of the
German drug surveillance system, Arzneimittelsicherheit in der Psychiatrie (AMSP) (AD, antidepressant; AP, antipsychotic;















Fig. 4. Prevalence of combination of antipsychotics with other psychopharmaca in % of schizophrenic inpatients. Data of
the German drug surveillance System (AP, antipsychotic; TR, tranquilizer; AD, antidepressant; AEP, antiepileptic;
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In Austria the number of psychotropic medications
per patient tends to be somewhat higher (5.3) com-
pared to Switzerland (4.5) und Germany (4.1). In
an additional analysis it was demonstrated that, in par-
ticular, the increase above three medications is associ-
ated with a higher frequency of severe side effects
and even death (Grohmann oral communication).
Thus the problematic aspects of comedication/
polypharmacy become obvious.
It is difficult to compare these data on the preva-
lence of comedication/polypharmacy with data from
other studies and from other regions of the world.
There are too many differences in terms of the avail-
ability of specific compounds in some countries and
the way data were collected or analysed. In spite of
all these methodological differences, the general out-
come results might be seen as similar: a large amount
of comedication/polypharmacy (Mojtabai and Olfson,
2010) often accompanied by a recent increase, similar
to the above two studies from Germany. This seems
to go far beyond evidence-based indications for come-
dication and polypharmacy (Frye et al., 2000; Kotzan
et al., 2002; Stahl and Grady, 2004; Aparasu et al.,
2005; Baghai et al., 2006; Gilmer et al., 2007; Haider
et al., 2007; Glezer et al., 2009; Karagianis et al., 2009;
McIntyre and Jerrell, 2009).
A few studies touched on the problems of pharma-
cokinetic interaction and increased number of side
effects (Daniel et al., 1994; Heeringa et al., 1999;
Freudenreich and Goff, 2002; Spina et al., 2002;
Gardos, 2005; Ito et al., 2005; Tranulis et al., 2008) in
connectionwithcomediation/polypharmacy.Pharmaco-
economical issues of comedication/polypharmacy
(increase of costs) have so far not been empirically
analysed very much (Clark et al., 2002; Valuck et al.,
2007; Zhu et al., 2008; Poeschla et al., 2011).
Conclusions
Comedication and even polypharmacy are meaning-
ful and rational under certain conditions (Preskorn
and Lacey, 2007). From a clinical viewpoint it
might probably be going too far to always ask
for a proven accordance to the strict rules of
evidence-based medicine, because it is too complicated
to do so for all combinations judged as suitable from a
clinical or theoretical perspective (Möller and Maier,
2010).
Interestingly, in a recent survey it was found
that high antipsychotic polypharmacy prescribers
had more clinical experience and fewer concerns
about the risks of polypharmacy (Correll et al., 2011).
This underlines that comedication/polypharmacy is
probably not induced only by lack of knowledge.
Hence, it would be naïve to ban comedication/
polypharmacy a priori. Instead, a more differentiated
understanding and approach is necessary. Comedica-
tion, and especially polypharmacy, should always be
considered critically in terms of benefits and risks
(Barnes and Paton, 2011), and strategies to reduce
polypharmacy should be implemented (Janssen et al.,
2004; Patrick et al., 2006; Thompson et al., 2008). In
addition, health care costs should be taken into account.
On the other hand, polypharmacy is one of the tools


















Fig. 5. Prevalence of combination of antidepressants with other antidepressants in % of depressed inpatients. Data of the
German drug surveillance system, Arzneimittelsicherheit in der Psychiatrie (AMSP) (SSRI, selective serotonin reuptake
inhibitor; SNRI, selective serotonin and noradrenalin reuptake inhibitor; NaSSA, noradrenergic specific serotonorgic
antidepressant; Mirta, mirtazapine; Venla, Venlafaxine; TCA, tricyclic antidepressant).
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From an educational perspective the condensed
thoughts suggested by Preskorn and Lacey (2007),
seem meaningful:
• Mono-drug therapy: the ideal;
• Co-pharmacy: commonly needed;
• Triple pharmacy: may be necessary;
• Quadruple pharmacy: first consider that three drugs
are not working.
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